Table 2.
Clinical Characteristics Pre- and Post-LVAD
| Pre-LVAD | Post-LVAD | P Value | |
|---|---|---|---|
| NYHA functional class, I/II/III/IV | 0/0/0/16 | 2/10/2/1a | <0.001 |
| LVEF, % | 14.2 ± 7.6 | 24.6 ± 13.0a | 0.019 |
| Fractional shortening, % | 6.3 ± 4.0 | 13.0 ± 7.3a | 0.003 |
| LVIDs, cm | 6.5 ± 1.2 | 4.7 ± 1.3a | <0.001 |
| LVIDd, cm | 7.0 ± 1.2 | 5.3 ± 1.2a | <0.001 |
| Heart rate, beats/min | 97.6 ± 20.9 | 88.9 ± 16.5 | 0.14 |
| Mean arterial pressure, mm Hg | 75.6 ± 11.4 | 82.3 ± 7.3 | 0.15 |
| Body weight, kg | 82.8 ± 17.8 | 81.7 ± 16.4 | 0.51 |
| Body surface area, m2 | 1.99 ± 0.23 | 1.98 ± 0.22 | 0.33 |
| Serum B-type natriuretic peptide, pg/mL | 1,765.6 ± 1,283.0 | 387.1 ± 599.6b | 0.002 |
| Serum total cholesterol, mg/dL | 121.1 ± 34.2 | 158.6 ± 28.2 | 0.003 |
| Serum creatinine, mg/dL | 1.27 ± 0.24 | 0.98 ± 0.21 | 0.001 |
| Medications | |||
| ACE inhibitor | 1 (6.3) | 9 (56.3) | 0.013 |
| Aldosterone antagonist | 14 (87.5) | 16 (100) | 0.48 |
| Antiarrhythmic agent | 4 (25.0) | 4 (25.0) | 0.62 |
| Beta-blocker | 2 (12.5) | 11 (68.8) | 0.008 |
| Digoxin | 8 (50.0) | 5 (31.3) | 0.45 |
| Dobutamine | 13 (81.3) | 0 (0.0) | <0.001 |
| Hydralazine | 3 (18.8) | 3 (18.8) | 0.68 |
| Loop diuretic | 14 (87.5) | 9 (56.3) | 0.13 |
| Milrinone | 2 (12.5) | 1 (6.3) | >0.99 |
| PDE5 inhibitor | 0 (0.0) | 1 (6.3) | >0.99 |
| Statin | 0 (0.0) | 2 (12.5) | 0.48 |
| Warfarin | 0 (0.0) | 14 (87.5) | <0.001 |
Values are mean ± SD or n (%). For medications, data are listed as n (%). Italic values indicate statistical significant.
ACE = angiotensin-converting enzyme; LVAD = left ventricular assist device; LVEF = left ventricular ejection fraction; LVIDd = left ventricular internal diameter during diastole; LVIDs = left ventricular internal diameter during systole.
a
Not measured in 1 patient.
b
Not measured in 7 patients. Data analysis by McNemar’s test for paired categorical data for NYHA functional class and medications. Data analysis by 2-tailed paired Student's t-test for all other comparisons.